disopyramide has been researched along with Chronic Kidney Failure in 14 studies
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Disopyramide is a group I antiarrhythmic drug which is mainly used for the treatment of ventricular and supraventricular rhythm disturbances." | 5.28 | Disopyramide-induced hypoglycemia: case report and review of the literature. ( Baumelou, A; Cacoub, P; Deray, G; Grimaldi, A; Jacobs, C; Soubrie, C, 1989) |
| "Twenty-nine cases of hypoglycemia induced by disopyramide (DP) have been reported in the literature to date." | 3.68 | [Accumulation of a disopyramide metabolite in renal failure]. ( Amano, I; Inagaki, Y; Ito, T; Masamoto, S; Niwa, M; Otsu, T, 1993) |
| " The pharmacokinetic parameters were calculated using a two-compartment model." | 1.28 | Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure. ( Hatano, M; Inoue, M; Kuno, T; Maeda, H; Maejima, M; Nagura, Y; Okada, K; Takahashi, S; Yanai, M, 1991) |
| "Disopyramide is a group I antiarrhythmic drug which is mainly used for the treatment of ventricular and supraventricular rhythm disturbances." | 1.28 | Disopyramide-induced hypoglycemia: case report and review of the literature. ( Baumelou, A; Cacoub, P; Deray, G; Grimaldi, A; Jacobs, C; Soubrie, C, 1989) |
| " With the exception of maximum concentration (C max), which was only slightly modified, and of the apparent distribution volume which remained unchanged, all the other pharmacokinetic blood parameters (t max, concentration at 24th hour, elimination constant (ke h-1), elimination half-life, area under the curve and plasma clearance) were significantly modified in the CRF group; in particular, the elimination half-life was significantly increased (for 22 cases of CRF with mean plasma creatinine greater than 250 microM at 16." | 1.27 | Pharmacokinetics of disopyramide in patients with chronic renal failure. ( Francois, B; Lussignol, M; Mallein, R; Rondelet, J, 1983) |
| " 2 Absorption half-life and volume of distribution were similar to those seen in normal subjects." | 1.26 | Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment. ( Hamer, NA; Henry, JA; Johnston, A; Warrington, SJ, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (71.43) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Francois, B | 1 |
| Mallein, R | 1 |
| Rondelet, J | 1 |
| Lussignol, M | 1 |
| Burk, M | 1 |
| Peters, U | 1 |
| Risler, T | 1 |
| Grabensee, B | 1 |
| Johnston, A | 2 |
| Henry, JA | 2 |
| Warrington, SJ | 2 |
| Hamer, NA | 2 |
| Otsu, T | 1 |
| Ito, T | 1 |
| Inagaki, Y | 1 |
| Amano, I | 1 |
| Masamoto, S | 1 |
| Niwa, M | 1 |
| Kaji, T | 1 |
| Nojima, Y | 1 |
| Arisaka, H | 1 |
| Naruse, T | 1 |
| Story, JR | 1 |
| Abdulla, AM | 1 |
| Frank, MJ | 1 |
| Pugh, DM | 1 |
| Karim, A | 1 |
| Nagura, Y | 1 |
| Kuno, T | 1 |
| Yanai, M | 1 |
| Maejima, M | 1 |
| Okada, K | 1 |
| Maeda, H | 1 |
| Inoue, M | 1 |
| Takahashi, S | 1 |
| Hatano, M | 1 |
| Belpaire, FM | 1 |
| Bogaert, MG | 1 |
| Cacoub, P | 1 |
| Deray, G | 1 |
| Baumelou, A | 1 |
| Grimaldi, A | 1 |
| Soubrie, C | 1 |
| Jacobs, C | 1 |
| Pedersen, LE | 1 |
| Bonde, J | 1 |
| Graudal, NA | 1 |
| Backer, NV | 1 |
| Hansen, JE | 1 |
| Kampmann, JP | 1 |
| Pellegrino, L | 1 |
| Prencipe, D | 1 |
3 trials available for disopyramide and Chronic Kidney Failure
| Article | Year |
|---|---|
Clinical pharmacokinetics and effects of an oral sustained-release preparation of disopyramide prescribed for patients undergoing maintenance hemodialysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined | 2000 |
Clinical studies of Norpace (Part VI).
Topics: Adult; Anti-Arrhythmia Agents; Anticoagulants; Arrhythmias, Cardiac; Bradycardia; Clinical Trials as | 1975 |
The pharmacokinetics of Norpace.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Carbon Radioisotopes; Chemical Phenomena; Chemistry; C | 1975 |
11 other studies available for disopyramide and Chronic Kidney Failure
| Article | Year |
|---|---|
Pharmacokinetics of disopyramide in patients with chronic renal failure.
Topics: Adolescent; Adult; Aged; Biotransformation; Disopyramide; Female; Half-Life; Humans; Kidney Failure, | 1983 |
[Dosage of disopyramid in insufficient renal function].
Topics: Aged; Creatinine; Disopyramide; Humans; Kidney Failure, Chronic; Middle Aged; Pyridines | 1982 |
Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.
Topics: Adolescent; Adult; Aged; Disopyramide; Female; Half-Life; Humans; Kidney Failure, Chronic; Male; Mid | 1980 |
[Accumulation of a disopyramide metabolite in renal failure].
Topics: Adult; Aged; Aged, 80 and over; Disopyramide; Female; Humans; Hypoglycemia; Kidney Failure, Chronic; | 1993 |
Influence of renal failure on disopyramide pharmacokinetics [proceedings].
Topics: Disopyramide; Humans; Kidney Failure, Chronic; Kinetics; Pyridines | 1979 |
Cardiogenic shock and disopyramide phosphate.
Topics: Acute Disease; Arrhythmias, Cardiac; Cardiac Output; Disopyramide; Heart Failure; Humans; Kidney Fai | 1979 |
Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure.
Topics: Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Disopyramide; Female; Half- | 1991 |
Binding of alfentanil to human alpha 1-acid glycoprotein, albumin and serum.
Topics: Adult; Aged; Alfentanil; Arthritis, Rheumatoid; Disopyramide; Female; Humans; Kidney Failure, Chroni | 1991 |
Disopyramide-induced hypoglycemia: case report and review of the literature.
Topics: Aged; Blood Glucose; C-Peptide; Disopyramide; Humans; Hypoglycemia; Insulin; Kidney Failure, Chronic | 1989 |
Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function.
Topics: Adult; Aged; Coronary Disease; Disopyramide; Female; Humans; Kidney Failure, Chronic; Liver Cirrhosi | 1987 |
[Disopyramide in the therapy and prevention of chronic atrial fibrillation. Study of 50 cases].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arteriosclerosis; Atrial Fibrillation; Coronary Disease; Disopy | 1973 |